Teladoc stock is undervalued, with potential for significant revenue increases, according to Citron Research.

From Yahoo Finance: 2025-06-24 16:43:00

Teladoc (TDOC) shares are on the rise after Citron Research compared them to a “coiled spring” with potential to surge. The equity research firm believes TDOC is undervalued, especially with the recent acquisition of UpLift set to boost revenue. TDOC is down 45% from its year-to-date high.

Citron sees Teladoc’s acquisition of UpLift as “transformational” for revenue growth. The company is integrating BetterHelp into covered benefits, enhancing profitability. Teladoc’s scale and AI integration make it a strong investment choice, with potential for significant revenue increases.

Teladoc’s focus on AI integration could lead to improved profitability. A small increase in conversion rates could bring in $40 million in additional annual revenue. Citron emphasizes the long-term potential of owning TDOC shares due to the company’s commitment to removing barriers in healthcare.

TDOC reported strong Q1 results and provided in-line guidance for the current quarter. Wall Street analysts have a “Moderate Buy” rating on Teladoc stock, with a mean target price of $9.22, indicating a potential 15% upside. Investors should consider the growth potential and positive outlook for TDOC shares.

Read more: Teladoc Stock Is a ‘Coiled Spring’ That Could Surge Higher. Should You Buy TDOC Here?